COVID-19: Pfizer-BioNTech vaccine trial for children aged under 12 shows 'robust immune response'

A Pfizer-BioNTech COVID-19 vaccine trial for children aged between five and 11 has produced "positive results" and has shown a "robust immune response", the two firms have said.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting